Overview

Safety and Pharmacokinetics of SIM0417 Combined With Ritonavir in Healthy Elderly Subjects

Status:
Recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
This is a non-randomized, open-label, single-dose, Phase I clinical study and plans to enroll 12-20 healthy elderly subjects aged 65 and above, including 3-6 subjects aged 75 and above, both men and women.
Phase:
Phase 1
Details
Lead Sponsor:
Jiangsu Simcere Pharmaceutical Co., Ltd.
Treatments:
Ritonavir